Parent-determined Oral Montelukast Therapy for Preschool Wheeze With Stratification for Arachidonate-5-Lipoxygenase (ALOX5) Promoter Genotype.

Trial Profile

Parent-determined Oral Montelukast Therapy for Preschool Wheeze With Stratification for Arachidonate-5-Lipoxygenase (ALOX5) Promoter Genotype.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2014

At a glance

  • Drugs Montelukast (Primary)
  • Indications Wheezing
  • Focus Therapeutic Use
  • Acronyms WAIT
  • Most Recent Events

    • 22 Apr 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 24 Nov 2012 Accrual to date is 105% according to United Kingdom Clinical Research Network.
    • 20 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top